USPTO serial 79264508
ABTIS
Reviewed by CopyMark Law Group
Reg. 6050283Status 708Renewal
- Filing date
- Status date
- Registration date
- May 12, 2020
- Examiner
- SETTLES LEWIS, SHAILA E
- Law office
- Historical data usage
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ABTIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $425
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Paul G. Johnson
Paul G. Johnson Maschoff Brennan1389 Center Drive, Suite 300Park City, UT 84098United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ Pharmaceutical agents affecting metabolism; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of cancer; chemical preparations for pharmaceutical purposes, namely, for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; biotechnological preparations for medical purposes, namely, for the treatment of oncological, metabolic and ophthalmic diseases and disorders; drugs for medical purposes, namely, for treating cancer; drugs for medical purposes, namely, for treating diabetes; drugs for medical purposes, namely, for treating ocular disease; antibodies for medical purposes, namely, for the treatment of oncological, metabolic and ophthalmic diseases and disorders; pharmaceutical compositions for the treatment of oncological, metabolic and ophthalmic diseases and disorders; medicines for human purposes for the treatment of oncological, metabolic and ophthalmic diseases and disorders; nutraceuticals for therapeutic purposes for the treatment of cancer; nutraceuticals for therapeutic purposes for the treatment of diabetes; therapeutic drugs and agents, namely, antibody drug conjugate comprising antibody and chemical compound attached for the treatment of oncological, metabolic and ophthalmic diseases and disorders; anti-cancer preparations ] | SECTION 71 - CANCELLED | — |
| 042 | Research and development of vaccines and medicines; biotechnology research; biological research; crude medicines research; scientific research for medical purposes in the field of cancerous diseases; research on the subject of pharmaceuticals; medical research; clinical research in the field of oncology, metabolic disease and ophthalmology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 29, 2026 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Jul 29, 2026 | C75P | REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Jul 27, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 17, 2026 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Apr 2, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 12, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jan 28, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 11, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 17, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 17, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 12, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 12, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 25, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 25, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 22, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 5, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 5, 2020 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 5, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 23, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 9, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 8, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 8, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 16, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 31, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 31, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 12, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 11, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 25, 2019 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Sep 13, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 12, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 10, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 20, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 15, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 8, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |